IFNA17 and Alzheimer disease: DUOX2 (Samadi et al., 2011), CDKN2A (Tedde et al., 2011; Antonell et al., 2016), HMGB1 (Alabed et al., 2021; Tanaka et al., 2021; Gao et al., 2022), BRD4 (Nikkar et al., 2022; Zhang et al., 2022) and PPARD (Holzapfel et al., 2006; Helisalmi et al., 2008) have been experimentally validated in the pathogenesis of AD, but NOX5, ALOX15, B, BAP1, IFNA17 and P4HB have never been studied to confirm their association with AD.